Malignant bone tumors arising in humans are generally difficult to cure, have a poor prognosis, and very often cause intolerable pain and disability.

Primary malignant bone tumors, although rare, tend to be more frequent in younger individuals and have a profound effect on the future of such patients. On the other hand, metastatic bone tumors are usually found in comparatively elderly patients, in whom they arise from malignancies such as carcinoma of the lung, breast, and prostate.

The prognosis is often unfavorable for such patients, because metastasis occurs after surgical treatment, radiotherapy, and/or chemotherapy for the primary tumor. Therefore, success with cancer therapy depends on both the curability of the primary lesion and the prevention of metastasis.

The mechanism of cancer metastasis has not yet been fully elucidated either experimentally or clinically. In this study, we prepared experimental bone metastases in rats, and subjected the resulting lesions to histologic and radiologic examination.

Materials and methods

**Animals**

This study used inbred female Fischer-344 rats purchased from Japan Clea Co. (Tokyo). Two animals were housed together in stainless steel cages which were kept in an air-conditioned clean room at 25 ± 1°C throughout the experiment. The animals were provided with a pellet diet (CE-2, Japan Clea Co., Tokyo) and tap water ad libitum.

**Induction of mammary cancer**

Mammary cancer was induced with an olive oil solution of 7, 12-dimethylbenz (a) anthracene (DMBA) (Eastman Kodak Co., Rochester, USA), which was given orally to the rats twice at the ages of 8 and 9 weeks (30mg/kg each time). The rats given DMBA were examined once a week to detect the development of cancer and tumor masses which grew to 2 ~ 3cm in diameter were dissected out for transplantation.

**Transplantation**

The DMBA-induced mammary cancers were histologically shown to be adenocarcinomas.

The dissected tumor tissue was cut into thin slices with scissors under sterile conditions, and was made into a cell suspension by simple mechanical compression using rubber. After phosphate-buffered saline (pH7.4) containing 1% trypsin (Difco co., 250 : 1) was added to the tumor suspension for digestion, cancer cells were isolated by centrifugation at 600G. Then the isolated cells were suspended again, and 1 × 10^6 cells (1ml) were injected subcutaneously into rats of the same strain at the mammary line of the ventral chest wall. Mammary cancer cells which acquired
transplantability by this procedure were subsequently maintained by injecting them into the subcutaneous tissue of the lateral chest wall of rats of the same strain every 6 weeks.

Transplantation of mammary cancer cells into medullary cavity

Intraosseous transplantation of mammary cancer cells was done by inoculating $1 \times 10^6$ cancer cells ($50 \mu l$ of cell suspension) into the left femoral medullary cavity of rats by direct injection with 21 G needle through the anterior intercondylar fossa under Nembutal anesthesia (Fig.1A).

Histological examination

Bone tissue for histological examination was operatively resected with scissors, fixed in 10% phosphate-buffered formalin solution for 1 week, and then decalcified in 3% ethylenediaminetetraacetic acid sodium salt solution (EDTA). The tissue was then embedded in paraffin and stained with hematoxylin and eosin.

Radiography and X-ray irradiation

Radiographs were taken using a portable X-ray machine (KCD-10M-6AT, Toshiba Co., Tokyo), and X-
Ray irradiation was performed using a 4 MeV linear accelerator (Linac, NEC, Tokyo).

Statistical analysis
Calculation of cumulative survival rates was done by the Kaplan-Meier method, while statistical analysis of the significance of differences was done with the generalized Wilcoxon test.

Results

Induction and transplantation of mammary cancer
DMBA was given orally to 48 female Fischer rats from the age of 8 weeks, and 45 of them survived for at least 25 weeks. Macroscopic cancer growth was observed in 37 rats by 25 weeks after administration. These tumors were categorized as follows: 8 papillary adenocarcinomas, 13 medullary carcinomas, 2 scirrhou carcinomas, 14 fibroadenomas, 5 mixed malignancies comprising papillary adenocarcinoma and medullary carcinoma, and 14 mixed tumors comprising adenocarcinoma and fibroadenoma. There were no tumors in 8 rats. All the papillary adenocarcinomas and medullary carcinomas were subjected to transplantation, and these cancers were all successfully transplanted. In the present study, one of these transplantable mammary tumors was used.

When the transplantable mammary cancer cells obtained as mentioned above were injected into the femoral medullary cavity, they continued to proliferate in all cases, causing osteolysis and periosteal new bone formation (Fig.1) that was followed by fracture. Finally, after progressive bone destruction (Fig.5), the rats died while bearing large cancers which had grown very rapidly.

Characteristics of tumor proliferation in bone
Fig.2 show the cumulative survival rate data for rats inoculated with $1 \times 10^6$ cancer cells into the subcutaneous tissue of the lateral chest wall or into the femur, and for rats which underwent X-ray irradiation (45 Gy) of the tumor-injected bone at 1 week after inoculation. Fig.3 shows a Lineac radiograph taken for verification.

Fig.3 Arrangement of the anterior field for a rat femur with transplantable mammary cancer (A) and verification film obtained for irradiation with the 4 MeV linear accelerator (B).

Fig.4 Light microphotograph of a lung metastasis of the transplantable mammary cancer Pulmonary metastases occurred in all of the rats after transplantation (hematoxylin and eosin stain, ×320).
As shown in Fig. 2, the mean survival time was 21.1 ± 11.3 days, after the intraosseous transplantation of cancer cells, and was significantly shorter than after subcutaneous transplantation (47.5 ± 24.7 days, p < 0.01). In the rats which received intraosseous transplantation, X-ray irradiation prolonged the mean survival time to 34.8 ± 14.4 days (p < 0.05).

When transplantable mammary cancer cells were injected into the femoral medullary cavity, pulmonary metastases almost always developed at an early stage following inoculation. Figure 4 shows the histological appearance of pulmonary metastases 5 days after the intraosseous transplantation of cancer cells. No pulmonary metastasis developed in any of the rats given subcutaneous inoculations of mammary cancer cells.

Radiographic bone changes after cancer cell transplantation

After the transplantation of cancer cells, radiography demonstrated osteolysis and a moth-eaten appearance indicating bone destruction along with disruption of the cortex and the growth of extrasosseous soft tissue masses. (Fig. 1B-D).

In almost all the rats receiving intraosseous transplantation, periosteal spiculation appeared about one week after inoculation.

Fig. 5 (A-D) shows femoral radiographs taken at weekly intervals after the intraosseous inoculation of cancer cells. The radiographs in Fig. 5 (E-H) show cancer cell-injected bone which received X-ray irradiation at 1 week after inoculation. When the femur was irradiated (45 Gy) after intraosseous tumor inoculation, bone destruction ceased or was delayed.

Histological bone changes after cancer cell transplantation

When cancer cells were injected into the medullary cavity, the surrounding tissues underwent sudden changes. Fig. 6 shows a photomicrograph of the endosteum and periosteum in the metaphyseal region obtained 11 days after inoculation of transplantable mammary cancer cells into the femoral marrow cavity. Bone resorption by osteoclasts can be seen to affect both the endosteum and the periosteum.

Discussion

There have been numerous studies on bone metastasis, but the mechanism involved has still not been elucidated. The question of which cells can act as osteoclast progenitor cells is an important theme of current research in this field.

In this study, a rat model of bone metastasis was prepared by inoculating transplantable mammary cancer cells into inbred Fischer rats, and the bone lesion were examined radiographically and microscopically. We demonstrated that transplanted mammary cancer cells caused bone resorption at both the endosteal and periosteal surfaces within a few days after inoculation, and subsequently shortened the life span of the rats as
bone destruction progressed.

Among the previous studies on experimentally induced bone metastases, those using rabbit VX2 tumor reported by Galasko7) and by Cerino and King et al.8) are well known. VX2 carcinoma is a transplantable rabbit tumor that is frequently used for experimental purposes. Galasko et al. have performed numerous radiological and histological studies of this tumor9). Both Cerino et al. and Galasko et al. inject VX2 carcinoma cells into the marrow of the rabbit tibia through a hole made with a dental drill. The rat is the most frequently used experimental animal next to the mouse. Dixon et al. have studied lymph node metastasis using transplantable mammary cancer cells and the inbred rats10).

More recently, Yamasaki et al.11) prepared an animal model of bone metastasis using transplantable osteogenic tumors obtained by the administration of radioactive phosphorus to rats. Transplantable osteogenic tumor cells were injected subperiosteally into the tibia.

We prepared transplantable mammary carcinoma cells by the serial transplantation of mammary cancers produced by administration of a chemical carcinogen to inbred rats. These transplantable mammary cancer cells were injected with 21 G needle into the femoral marrow of rats to prepare a model of bone metastasis. After transplantation of the mammary cancer cells, bone resorption by osteoclasts affected both the endosteum and periosteum, new bone formation by osteoblasts occurred on the surface of the periosteum, and a series of phenomena involving bone remodeling and fracture were observed due to accelerated bone resorption by activated osteoclasts in association with rapid tumor proliferation.

The general course of tumor metastasis is that tumor cells from the primary lesion arrive in an organ through the blood stream or lymph flow, grow until the affected organ is destroyed, and eventually cause the death of the host.

The model of cancer metastasis developed in this series of experiments is considered to reflect these characteristics of cancer behaviour. Although it is not a natural mode of metastasis making use of blood or lymph flow, direct take of tumor cells inside the target organ is possible. Furthermore, this method is simple to perform and uses a tumor derived from the same strain of rats. It is also feasible to manipulate the animals easily because of their medium size.

The issues to be studied in the future include histologic and physiologic clarification of the generation of osteoblasts and osteoclasts in the endosteum and periosteum following the transplantation of cancer cells, as well as determination of the mechanism of bone resorption and new bone formation, and the radiation sensitivity of osteoblasts and osteoclasts. Further studies on these topics are in progress.

Acknowledgement: This work was supported in part by a Grant-in Aid for cancer research (T.M. : 60-4) from the Japanese Ministry of Health and Welfare.

References

Annals of Cancer Research and Therapy Vol.2 No.2 1993 197

Offprint request to: A. Ohta, Department of Radiology, Kitasato University School of Medicine, Sagamihara, Kanagawa 228, Japan
Rat model of bone metastasis obtained by mammmary cancer transplantation

Akishige Ohta et al.

骨転移に対する放射線の照射効果を実験的に調べるための動物モデルをつくることを目的として、近親系のラットに発癌物質を発癌させた乳癌細胞を骨髄腔に移植し、形態学的・X線学的検査を行い、骨転移ラットモデルの性質について検討した。

[対象と方法] 乳癌（腺癌）は、近親系雌雄のFischer-344系のラットに7,12-dimethylbenz (a) anthracene (DMBA) を経口投与して発癌させた。この乳癌を同系のラット皮下に移植して間代維持のできる移植性乳癌を得た。この移植性乳癌細胞を同系ラットの骨髄腔に注入して骨髄癌の動物モデルを作成した。

本研究では、乳癌細胞をラットの肺の部位から腸骨の骨髄腔に移植した時の動物の生存率の測定、X線写真および組織病理学的検査を行った。また、乳癌細胞を移植した腸骨関節にX線照射の影響も調べた。

[結果] 本実験で使用したラット移植性乳癌細胞は、同系のラットの皮下あるいは骨髄腔に移植すると、移植したラットの全例に生存した。

100万個の乳癌細胞をラットの皮下および骨に移植したときの生存日数は、それぞれ47±24日と21±11日であった。乳癌細胞を移植された骨では、移植後47日目頃からX線写真に骨内反応が認められた。

組織学的には移植後、内膜および骨膜表面の休止期の扁平な骨芽細胞層の近傍から多数の骨芽細胞と破骨細胞が発生し、腫瘍組織の増大に伴って、既存骨および新生骨の両部位における破骨細胞による骨溶解と腫瘍細胞による骨破壊が進行し、最終的に骨折が起こって動物は死に至った。乳癌細胞を骨に移植したラットでは、全例に乳癌の節を転移の源とし、一方、同系に皮下に移植したラットでは、乳癌の節への転移が認められなかった。乳癌細胞を移植した部位の骨をX線で照射するとラットの寿命は延長した。

Radioimmunolocalization of human colorectal carcinoma xenografts with F(ab)'2 fragments of anti-sialyl Lewis a monoclonal antibody (MoAb) and a case report of radioimmunoscintigraphy with the radiolabelled fragment on recurrent rectal carcinoma patient

Junichi Sakamoto et al.

大腸癌末期細胞HT-29の細胞表面に発現しているシアル化Lewis'抗原に対するモノクローナル抗体（MoAb）H-15を精製し、ペプシン、パラインによりFab, F(ab)'2のfragmentを作製して、in vitro, in vivoの両方においてdosimetry analysisを行い、腫瘍画像診断における有用性を検討した。

[対象と方法] in vitroの系では、whole MoAbとFab, F(ab)'2の抗原に対する親和性を大腸癌末期細胞株SW403をターゲットとして、mixed hemagglutination test (MHA) にて判定した。in vivoの系では、whole MoAbとFabの両抗原を用い、in vivoの視点から腫瘍の侵襲を示す指標を設け、両抗原の用量比により、腫瘍の増殖を抑制した。また、腫瘍細胞の局在を検討した。両抗原による重篤な副作用は認められなかった。

[結果] ヨード標識をしたwhole MoAbとFab, F(ab)'2の大腸癌細胞株SW403に対するMHAテストではwhole MoAbが×5, Fabが×10, F(ab)'2が×5×10の希釈まで反応を示した。この結果，H-15Fabに関しては，放射性ヨード標識はFab fragmentの抗原結合能がいちじるしく低下することが明らかになった。

in vivoの系においては、標識抗体投与後4～7日目において腫瘍の増殖度がwhole MoAbで×5, Fabで×10であり、腫瘍の増殖度がwhole MoAbで×3, F(ab)'2で×25, 腫瘍の増殖度がwhole MoAbで×1.5～1.8であるのに対して、F(ab)'2では×10とF(ab)'2 fragmentのより高い腫瘍特異的集積が明らかになった。また、%IDもF(ab)'2は移植大腸癌細胞0.56（whole MoAbでは0.36）で、移植マラーマの0.03（0.08）、血液0.09（0.25）、肝0.07（0.10）、正常臓器0.05（0.09）、筋0.02（0.06）と移植大腸癌細胞において高値を示していた。ノードマウスにおける画像診断では、F(ab)'2抗体投与後36時間で、移植大腸癌細胞に抗体の集積がみられ、whole MoAbに比し、早期に腫瘍画像が得ることができた。また、直腸癌末期の症例においてF(ab)'2を投与した1例では、投与後3日目において腫瘍画像が抽出され、臨床応用への有用性が示唆された。

[考察] wholeのMoAbに対しFab, F(ab)'2 fragmentの腫瘍画像診断に用いることは、①早ければ、②抗体の腫瘍へのAccess、③F(ab)'2による非特異的集積の減少などの利点があるといわれている。

今回の検討により、in vivo, in vitro、また臨床の場においてもF(ab)'2 fragmentの高度を腫瘍特異的集積が証明され、今後の臨床応用への有用性が示されたものと考えられる。

Prognostic value of sialyl-Tn antigen in gastric carcinoma

Kiyoshi Maeda et al.

近年、糖鎖抗原は腫瘍マーカーとして重要な位置を占めている。糖鎖性腫瘍マーカーの一つであるcarbohydrate antigen 19-9（CA19-9）、sialyl Lewis-1（SL1）などの基幹糖鎖を抗原としたものであるが、これに対しシリアルTnの